Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hepatocyte growth factor/scatter factor (HGF/SF), via its receptor c-MET, has been implicated to play a pivotal role in breast cancer development and progression.
|
11489839 |
2001 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
HGF and Met are therefore candidate targets for therapeutic intervention in the treatment of breast cancer.
|
11934261 |
2002 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
HGF is considered to be a marker of progression and of the aggressiveness of breast cancer; our data fully corresponds to this.
|
22199345 |
2011 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
HGF was highly expressed in breast cancer patients and was not associated with patient age, location, size or hormone receptor status of the tumor (P>0.05), however, HGF expression was associated with tumor‑node‑metastasis (TNM) clinical stage, histological grade, lymph node metastasis and prognosis (P<0.05).
|
25351134 |
2015 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hepatocyte growth factor induces breast cancer cell invasion via the PI3K/Akt and p38 MAPK signaling pathways to up-regulate the expression of COX2.
|
28861172 |
2017 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Hepatocyte growth factor/scatter factor expression and c-met in primary breast cancer.
|
8837300 |
1996 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Certain well-known oncogenes (MYC and HGF), cytokines (CSF2, IFNG and IL5) and microRNAs (miR-21, miR-155-5p and let-7) may participate in the ILF2 expression network in breast cancer.
|
30018709 |
2018 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cooperative Effect of Oncogenic <i>MET</i> and <i>PIK3CA</i> in an HGF-Dominant Environment in Breast Cancer.
|
30518672 |
2019 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Deregulation of hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (MET) signalling has been associated with poor clinical outcome in breast cancer and other cancers.
|
24910416 |
2014 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Detection of hepatocyte growth factor/scatter factor receptor (c-Met) in axillary drainage after operations for breast cancer using reverse transcriptase-polymerase chain reaction.
|
12793903 |
2003 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Eighty-eight cases of carcinoma of the breast were studied by immunohistochemistry and by in situ hybridization for HGF and c-Met expression.
|
11328532 |
2001 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Epigenetic regulation of HGF/Met receptor axis is critical for the outgrowth of bone metastasis from breast carcinoma.
|
28151481 |
2017 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Extracellular superoxide dismutase inhibits hepatocyte growth factor-mediated breast cancer-fibroblast interactions.
|
29296173 |
2017 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, decreased cell viability of Met receptor expressing breast cancer cells treated with delphinidin argues for a potential role of the agent in the prevention of HGF-mediated activation of various signaling pathways implicated in breast cancer.
|
18499206 |
2008 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genetically (siMET) or pharmacologically (INCB28060) targeting MET inhibited both HGF- and pre-OB CM- mediated BC cell migration.
|
26934743 |
2016 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we demonstrate that treatment of breast cancer cells sensitive to EGFR TKIs with recombinant HGF confers a resistance to EGFR TKIs.
|
22788954 |
2012 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we show that stimulation of breast cancer cells with the ligand for Met, hepatocyte growth factor, promotes invadopodia formation, and in aggressive gastric tumor cells where Met is amplified, invadopodia formation is dependent on Met activity.
|
22366451 |
2012 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we investigated whether HGFK1 is a key regulator of breast cancer bone metastasis.
|
22767217 |
2012 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we report that hepatocyte growth factor and hypoxia may contribute to breast carcinoma cell invasiveness by inducing the chemokine receptor CXCR4.
|
16112111 |
2005 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Herein we investigate the regulation of Brk kinase activity and cell migration in response to treatment of keratinocytes (HaCaT cells) and breast cancer cell lines (MDA-MB-231 and T47D cells) with hepatocyte growth factor (HGF) and macrophage stimulating protein (MSP), peptide ligands for Met and Ron receptors, respectively.
|
20687930 |
2010 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
High levels of HGF/SF have been correlated with poor prognosis in human breast carcinoma.
|
9221809 |
1997 |
Breast Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
In fact, inducing disassociation of MCF-7 and T47D cells in culture by treating with HGF/scatter factor resulted in a loss of CLDN-7 expression within 24 h. Silencing of CLDN-7 expression correlated with promoter hypermethylation as determined by methylation-specific PCR (MSP) and nucleotide sequencing in breast cancer cell lines (3/3), but not in IDCs (0/5).
|
12673207 |
2003 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In vitro and in vivo effects of suppressor of cytokine signalling 7 knockdown in breast cancer: the influence on cellular response to hepatocyte growth factor.
|
25162020 |
2014 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of HGF/SF-induced breast cancer cell motility and invasion by the HGF/SF variant, NK4.
|
10832594 |
2000 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Met and its ligand HGF are associated with clinical outcome in breast cancer.
|
27175600 |
2016 |